100 percent of the voting shares of Prime Bank of Central Florida, Titusville, Florida.

Board of Governors of the Federal Reserve System, March 4, 1996. Jennifer J. Johnson, *Deputy Secretary of the Board.* [FR Doc. 96–5454 Filed 3–7–96; 8:45 am]

BILLING CODE 6210-01-F

## Notice of Proposal to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The company listed in this notice has given notice under section 4 of the Bank Holding Company Act (12 U.S.C. § 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to commence or to engage de novo, or to acquire or control voting securities or assets of a company that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.25 of Regulation Y (12 CFR 225.25) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

The notice is available for inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act, including whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices" (12 U.S.C. § 1843). Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than March 18, 1996. A. Federal Reserve Bank of Philadelphia (Michael E. Collins, Senior Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105:

1. United Valley Bancorp, Inc., Philadelphia, Pennsylvania; to acquire at least 50 percent of the voting shares of Eagle Valley Financial Services, Inc., Philadelphia, Pennsylvania, and thereby to engage in mortgage banking activities, pursuant to § 225.25(b)(1) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, March 5, 1996.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 96–5578 Filed 3–7–96; 8:45 am] BILLING CODE 6210–01–F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

## Technical Advisory Committee for Diabetes Translation and Community Control Programs; Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

*Name:* Technical Advisory Committee for Diabetes Translation and Community Control Programs (TACDTCCP).

*Times and Dates:* 1 p.m.–4 p.m., April 3, 1996. 8 a.m.–12:30 p.m., April 4, 1996.

*Place:* Stouffer Mayflower Hotel, 1127 Connecticut Avenue, NW., Washington, DC 20036, telephone 202/347–3000.

*Status:* Open to the public, limited only by the space available.

*Purpose:* This committee is charged with advising the Director, CDC, regarding priorities and feasible goals for translation activities and community control programs designed to reduce risk factors, morbidity, and mortality from diabetes and its complications. The Committee advises regarding policies, strategies, goals and objectives, and priorities; identifies research advances and technologies ready for translation into widespread community practice; recommends public health strategies to be implemented through community interventions; advises on operational research and outcome evaluation methodologies; identifies research issues for further clinical investigation; and advises regarding the coordination of programs with Federal, voluntary, and private resources involved in the provisions of services to people with diabetes.

*Matters To Be Discussed:* Committee members will discuss opportunities and directions for the TACDTCCP, the status and direction of the National Diabetes Education Program, and goals and future areas of emphasis for the Division of Diabetes Translation.

Agenda items are subject to change as priorities dictate.

For More Information Contact: Cheryl Shaw, Program Specialist, Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, CDC, 4770 Buford Highway, NE, M/S K–10, Atlanta, Georgia 30341–3724; telephone: 488–5004.

Dated: March 1, 1996.

Carolyn J. Russell, Director, Management Analysis and Services Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 96–5589 Filed 3–2–96; 8:45 am] BILLING CODE 4163–18–M

## National Vaccine Advisory Committee (NVAC) Subcommittee on Immunization Coverage; Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following Federal advisory subcommittee meeting.

*Name:* NVAC Subcommittee on Immunization Coverage.

*Times and Dates:* 1:30 p.m.–5 p.m., March 18, 1996. 8:30 a.m.–5 p.m., March 19, 1996.

*Place:* Omni Shoreham Hotel, 2500 Calvert Street, NW., Washington, DC 20008, telephone (202) 234–0700.

*Status:* Open to the public, limited only by the space available.

*Purpose:* The Subcommittee on Immunization Coverage will identify strategies and policy options by which to further improve the levels of immunization coverage.

Matters to be Discussed. Agenda items include a discussion of previous NVAC financing of vaccine delivery issues and lessons from the past; vaccine cost issues: cost-benefit of first-dollar coverage, an actuary study, and administrative costs and insurance premiums; discussion of data needed in future studies and what we want to learn for tomorrow; and issues from the payor's and public perspective.

Agenda items are subject to change as priorities dictate.

*For More Information Contact:* Alison B. Johnson, Program Analyst, National Immunization Program, CDC (Corporate Square), 1600 Clifton Road, NE., M/S E52, Atlanta, Georgia 30333; telephone: (404) 639– 8222.

This notice is being published less than 15 days prior to the meeting due to problems associated with obtaining a meeting location.

Dated: March 1, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–5590 Filed 3–7–96; 8:45 am] BILLING CODE 4163–18–M